Your browser doesn't support javascript.
loading
Targeting S6K/NFκB/SQSTM1/Polθ signaling to suppress radiation resistance in prostate cancer.
Clark, Alison; Villarreal, Michelle R; Huang, Shih-Bo; Jayamohan, Sridharan; Rivas, Paul; Hussain, Suleman S; Ybarra, Meagan; Osmulski, Pawel; Gaczynska, Maria E; Shim, Eun Yong; Smith, Tyler; Gupta, Yogesh K; Yang, Xiaoyu; Delma, Caroline R; Natarajan, Mohan; Lai, Zhao; Wang, Li-Ju; Michalek, Joel E; Higginson, Daniel S; Ikeno, Yuji; Ha, Chul Soo; Chen, Yidong; Ghosh, Rita; Kumar, Addanki P.
Affiliation
  • Clark A; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Villarreal MR; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Huang SB; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Jayamohan S; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Rivas P; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Hussain SS; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ybarra M; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Osmulski P; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Gaczynska ME; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Shim EY; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Smith T; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Gupta YK; Departments of Greehey Children's Cancer Institute, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA; Department of Biochemistry and Structural Biology, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Yang X; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Delma CR; Departments of Pathology, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Natarajan M; Departments of Pathology, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Lai Z; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA; Departments of Greehey Children's Cancer Institute, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA; Departments of Mays Cancer Center, Long Sch
  • Wang LJ; Departments of Greehey Children's Cancer Institute, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Michalek JE; Departments of Mays Cancer Center, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA; Departments of Epidemiology and Biostatistics, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Higginson DS; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ikeno Y; Departments of Pathology, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA; Barshop Institute for Longevity and Aging Studies, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA; Audie L. Murphy VA Hospital (STVHCS), Long School of
  • Ha CS; Departments of Mays Cancer Center, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA; Department of Radiation Oncology, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Chen Y; Departments of Greehey Children's Cancer Institute, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA; Departments of Mays Cancer Center, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA.
  • Ghosh R; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA; Departments of Urology, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA; Departments of Pharmacology, Long School of Medicine, The University of
  • Kumar AP; Departments of Molecular Medicine, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA; Departments of Urology, Long School of Medicine, The University of Texas Health San Antonio, TX, 78229, USA; Departments of Pharmacology, Long School of Medicine, The University of
Cancer Lett ; 597: 217063, 2024 Aug 10.
Article in En | MEDLINE | ID: mdl-38925361
ABSTRACT
In this study we have identified POLθ-S6K-p62 as a novel druggable regulator of radiation response in prostate cancer. Despite significant advances in delivery, radiotherapy continues to negatively affect treatment outcomes and quality of life due to resistance and late toxic effects to the surrounding normal tissues such as bladder and rectum. It is essential to develop new and effective strategies to achieve better control of tumor. We found that ribosomal protein S6K (RPS6KB1) is elevated in human prostate tumors, and contributes to resistance to radiation. As a downstream effector of mTOR signaling, S6K is known to be involved in growth regulation. However, the impact of S6K signaling on radiation response has not been fully explored. Here we show that loss of S6K led to formation of smaller tumors with less metastatic ability in mice. Mechanistically we found that S6K depletion reduced NFκB and SQSTM1 (p62) reporter activity and DNA polymerase θ (POLθ) that is involved in alternate end-joining repair. We further show that the natural compound berberine interacts with S6K in a in a hitherto unreported novel mode and that pharmacological inhibition of S6K with berberine reduces Polθ and downregulates p62 transcriptional activity via NFκB. Loss of S6K or pre-treatment with berberine improved response to radiation in prostate cancer cells and prevented radiation-mediated resurgence of PSA in animals implanted with prostate cancer cells. Notably, silencing POLQ in S6K overexpressing cells enhanced response to radiation suggesting S6K sensitizes prostate cancer cells to radiation via POLQ. Additionally, inhibition of autophagy with CQ potentiated growth inhibition induced by berberine plus radiation. These observations suggest that pharmacological inhibition of S6K with berberine not only downregulates NFκB/p62 signaling to disrupt autophagic flux but also decreases Polθ. Therefore, combination treatment with radiation and berberine inhibits autophagy and alternate end-joining DNA repair, two processes associated with radioresistance leading to increased radiation sensitivity.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms / Radiation Tolerance / Signal Transduction / NF-kappa B / Sequestosome-1 Protein Limits: Animals / Humans / Male Language: En Journal: Cancer Lett Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms / Radiation Tolerance / Signal Transduction / NF-kappa B / Sequestosome-1 Protein Limits: Animals / Humans / Male Language: En Journal: Cancer Lett Year: 2024 Type: Article Affiliation country: United States